We are live on ! Find out more
NMTR

9 Meters Biopharma

Delisted

NMTR was delisted on the 25th of July, 2023.

88 hedge funds and large institutions have $13M invested in 9 Meters Biopharma in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

781% more call options, than puts

Call options by funds: $476K | Put options by funds: $54K

22% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 18

13% less funds holding

Funds holding: 10188 (-13)

41% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 29

71% less capital invested

Capital invested by funds: $45.2M → $13M (-$32.2M)

Holders
88
Holders Change
-13
Holders Change %
-12.87%
% of All Funds
1.48%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
22
Reduced
18
Closed
29
Calls
$476K
Puts
$54K
Net Calls
+$422K
Net Calls Change
-$906K

NMTR Hedge Fund Activity: Q2 2022 in Review

88 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q2 2022, worth a combined $13M — down 71% from $45.2M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of NMTR and 17 opened new positions — a net loss of 12 holders — while 18 trimmed existing stakes and 22 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.15M. The largest seller was BlackRock, cutting an estimated $5M.

  • 88 institutional investors held 9 Meters Biopharma (NMTR) as of Q2 2022, down from 101 in Q1 2022.
  • Funds reported $13M of 9 Meters Biopharma stock for Q2 2022, down 71% quarter-over-quarter.
  • 17 funds opened new 9 Meters Biopharma positions in Q2 2022 and 29 closed out, a net change of -12 holders.
  • The largest 9 Meters Biopharma buyer in Q2 2022 was Laurion Capital Management, an estimated $2.15M added.
  • The largest 9 Meters Biopharma seller in Q2 2022 was BlackRock, an estimated $5M sold.

Based on aggregated 13F filings for Q2 2022.